ADVERSE REACTIONS SECTION.
ADVERSE REACTIONS. Adverse reactions from topical use of ALOQUIN is expected to be low when used as directed, due to low concentration of Iodoquinol present in this topical gel.To achieve the equivalent of common daily oral dose of nearly 2,000 mg Iodoquinol, one will need to use more than full tubes of 60 ALOQUIN in single application. Adverse reactions from oral form of Iodoquinol (nearly 2,000 mg daily) have been reported: various forms of skin eruptions, hives, itching, nausea, vomiting, abdominal cramps, diarrhea, anusitis, fever, chills, headache, vertigo and enlargement of thyroid.
Citing DrugCentral © 2024. License
CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.
Carcinogenesis, Mutagenisis and Impairment of Fertility. Long term animal studies have not been performed to evaluate the carcinogenic potential of the effect on fertility of Iodoquinol. Mutagenicity studies have not been performed with Iodoquinol.
Citing DrugCentral © 2024. License
CONTRAINDICATIONS SECTION.
CONTRAINDICATIONS. ALOQUIN is contraindicated in those patients with history of hypersensitivity to any components of the preparation.
Citing DrugCentral © 2024. License
DESCRIPTION SECTION.
DESCRIPTION. Each gram of ALOQUIN contains 1.25% (12.5 mg) Iodoquinol and 1% (10mg) Aloe Polysaccharides. Other ingredients: Purified Water, Carbomer 980, Magnesium Aluminum Silicate, PEG-20 Methyl Glucose Ether, Aminomethyl Propanol 95, Biopeptide, Propylene Glycol, Glycerine, SDA Alcohol 40 B, Benzyl Alcohol, Trolamine, FD&C Blue and D&C Yellow 10.. Iodoquinol. Iodoquinol is an antifungal and antibacterial agent. Chemically, Iodoquinol is [5,7-diiodo-8-quinolinol] with the molecular formula (C9H5I2NO) and is represented by the following structural formula:. Aloe Polysaccharide. The Aloe Polysaccharide in ALOQUIN is patented mixture of acetylated mannan aloe polysaccharide. Each purified acetylated mannan polysaccharide of specific molecular weight range and average is composed of the same repeating subunits shown below (where is mannose, is galactose and is glucose monomers):. Chemical Structure. Chemical Structure.
Citing DrugCentral © 2024. License
DOSAGE & ADMINISTRATION SECTION.
DOSAGE AND ADMINISTRATION. Apply to affected areas 3-4 times daily or as directed by physician. Follow your physicians directions regarding length of treatment after symptoms resolve.
Citing DrugCentral © 2024. License
HOW SUPPLIED SECTION.
HOW SUPPLIED. NDC 68040-706-1660 gram gel tubeNDC 68040-706-011 gram gel individual packNDC 68040-706-0810-count carton of gram gel sample packs not for resaleEach gram gel pack contains multiple doses depending on the surface area treated.. STORAGE. Store at room temperature 15-30C (59-86F). Keep tightly closed.
Citing DrugCentral © 2024. License
INDICATIONS & USAGE SECTION.
INDICATIONS AND USAGE. Based on review of related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: Possibly Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation.
Citing DrugCentral © 2024. License
NURSING MOTHERS SECTION.
Nursing Mothers. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ALOQUIN is administered to nursing woman.
Citing DrugCentral © 2024. License
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.
PRINCIPAL DISPLAY PANEL 60g Carton. NDC 68040-706-16AloQuin(TM) GEL 1.25% iodoquinol 1% aloe polysaccharidesContains Moisturizers For Dermatological Use OnlyRx OnlyBiopeptide Aloe Complex(TM)Deeper Penetration Patented FormulaNet Wt. 60g. PRINCIPAL DISPLAY PANEL 60g Carton.
Citing DrugCentral © 2024. License
PEDIATRIC USE SECTION.
Pediatric Use. Safety and effectiveness in pediatric patients under the age of 12 have not been established.
Citing DrugCentral © 2024. License
PREGNANCY SECTION.
Pregnancy Category C. Animal reproductive studies have not been conducted with ALOQUIN. It is not known whether ALOQUIN can cause fetal harm when administered to pregnant women or can affect reproductive capacity. ALOQUIN should be given to pregnant women only if clearly needed.
Citing DrugCentral © 2024. License
SPL UNCLASSIFIED SECTION.
Prescribing Information.
Citing DrugCentral © 2024. License
STORAGE AND HANDLING SECTION.
STORAGE. Store at room temperature 15-30C (59-86F). Keep tightly closed.
Citing DrugCentral © 2024. License
TERATOGENIC EFFECTS SECTION.
Animal reproductive studies have not been conducted with ALOQUIN. It is not known whether ALOQUIN can cause fetal harm when administered to pregnant women or can affect reproductive capacity. ALOQUIN should be given to pregnant women only if clearly needed.
Citing DrugCentral © 2024. License
WARNINGS AND PRECAUTIONS SECTION.
WARNINGS AND PRECAUTIONS. For external use only. Keep away from eyes. If irritation develops, the use of ALOQUIN should be discontinued and appropriate therapy instituted. Some discoloration of the skin, hair and fabrics may occur, but can be removed with normal cleansing and laundry. Not intended for use on infants or under diapers or occlusive dressings.Iodoquinol may be absorbed through the skin and interfere with thyroid function tests. If such tests are contemplated, wait at least one month after discontinuance of therapy to perform these tests. The ferric chloride test for phenylketonuria (PKU) can yield false positive result if Iodoquinol is present in the diaper or urine. Prolonged use may result in overgrowth of non-susceptible organisms requiring appropriate therapy. Keep out of reach of children.. Carcinogenesis, Mutagenisis and Impairment of Fertility. Long term animal studies have not been performed to evaluate the carcinogenic potential of the effect on fertility of Iodoquinol. Mutagenicity studies have not been performed with Iodoquinol.. Pregnancy Category C. Animal reproductive studies have not been conducted with ALOQUIN. It is not known whether ALOQUIN can cause fetal harm when administered to pregnant women or can affect reproductive capacity. ALOQUIN should be given to pregnant women only if clearly needed.. Nursing Mothers. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ALOQUIN is administered to nursing woman.. Pediatric Use. Safety and effectiveness in pediatric patients under the age of 12 have not been established.
Citing DrugCentral © 2024. License